|1.||Cazzola, Mario: 31 articles (09/2015 - 01/2004)|
|2.||Matera, Maria Gabriella: 15 articles (09/2015 - 01/2004)|
|3.||Hanania, Nicola A: 14 articles (01/2015 - 05/2005)|
|4.||Donohue, James F: 12 articles (08/2015 - 08/2004)|
|5.||Barnes, Peter J: 11 articles (09/2015 - 09/2002)|
|6.||Tashkin, Donald P: 11 articles (01/2014 - 08/2003)|
|7.||Ulrik, Charlotte Suppli: 10 articles (12/2015 - 01/2006)|
|8.||Fabbri, Leonardo M: 10 articles (02/2015 - 01/2003)|
|9.||O'Donnell, Denis E: 9 articles (01/2015 - 05/2003)|
|10.||Calverley, Peter M A: 9 articles (10/2014 - 05/2006)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2014 - "All guidelines recommend bronchodilators as baseline therapy for all stages of COPD, and long-acting inhaled bronchodilators, both beta-2 agonist (LABA) and antimuscarinic (LAMA) drugs, are the most effective in regular treatment in the clinically stable phase. "
08/01/2000 - "However, since physicians must always choose a drug that is highly efficacious, well tolerated and inexpensive, the cost-effectiveness analysis in relation to other bronchodilators will determine the proper place of long-acting beta2 agonists in the long term therapy of stable COPD."
01/01/2013 - "An increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single drug, and that these combinations are well tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). "
10/01/2013 - "Novel once-daily dosing bronchodilators, such as the long-acting muscarinic antagonist (LAMA) glycopyrronium and the LAMA/long-acting β2-agonist (LABA) fixed-dose combination QVA149, have been shown to provide significant benefits to patients with COPD in terms of improvement in lung function, exercise tolerance, health-related quality of life, symptoms and reduction in the rate of exacerbations. "
11/01/2007 - "Combining bronchodilators has been shown to be beneficial in patients with COPD. "
|2.||Asthma (Bronchial Asthma)
04/01/2012 - "Nebulized BUD in high dose and at short intervals combined with rapid-acting bronchodilators has an additional bronchodilator response, associated with more rapid and better improvement in clinical symptoms and lung function, indicating that it is preferred in the early management of acute moderate to severe exacerbation of asthma in children."
01/01/1993 - "A statistically significant reduction in clinical symptoms of bronchial asthma and bronchodilators usage was noted."
01/01/1985 - "The number of acute asthma attacks during the night, the number of symptom-free nights and the use of extra bronchodilators during the night were all significantly improved by SRT treatment (P less than 0.001). "
11/01/1996 - "Our data indicate that 1800 micrograms of per day is more effective than 1400 micrograms/day at the beginning of long-term management of severe asthma in adults whose symptoms are not controlled with the combination of 800 approximately 900 micrograms/day BDP and bronchodilators. "
05/01/1996 - "These data indicate that 1800 micrograms of BDP per day is more effective than 1400 micrograms/day at the beginning of long-term management of severe chronic asthma in adults whose symptoms are not controlled with the combination of 800 micrograms/day BDP and bronchodilators. "
|3.||Obstructive Lung Diseases (Obstructive Lung Disease)
06/01/2013 - "TAS2R agonists show promise as a new class of highly efficacious bronchodilators for treatment of obstructive lung disease. "
07/01/2015 - "Why use long acting bronchodilators in chronic obstructive lung diseases? "
04/01/2014 - "These agents have been proposed as a new class of bronchodilators in the treatment of obstructive lung diseases because they act via a different mechanism than β-agonists. "
11/01/2011 - "To identify the role of bronchodilators in the maximal breath-hold time in patients with obstructive lung disease (OLD). "
11/01/2010 - "Given the need for efficacious bronchodilators for treating obstructive lung diseases, this pathway can be exploited for therapy with the thousands of known synthetic and naturally occurring bitter tastants."
11/01/2003 - "Evidence-based emergency medicine/systematic review abstract: Are bronchodilators effective in bronchiolitis?"
03/01/2009 - "Despite the common clinical practice, the available evidence on the efficacy of bronchodilators therapy for bronchiolitis is conflicting. "
08/01/1997 - "To determine the efficacy of bronchodilators in the treatment of bronchiolitis. "
08/01/1997 - "Much controversy revolves around the efficacy of bronchodilators in the treatment of bronchiolitis. "
08/01/1997 - "Efficacy of bronchodilators in the treatment of bronchiolitis."
|5.||Respiratory Sounds (Crackle)
02/01/2013 - "Generalized wheezing was the most common lung sign detected in 73% of cases (11 cases) and 36% (4 cases) of them responded well to bronchodilators. "
09/01/1992 - "Marked stridor and orthopnea were observed, and auscultation of the chest revealed widespread expiratory wheeze which was not relieved by bronchodilators administered intravenously. "
01/01/2006 - "The inclusion of studies that enrolled infants with recurrent wheezing may have biased the results in favor of bronchodilators. "
08/01/2015 - "Case 1: Wheezing Unresponsive to Bronchodilators in a 4-month-old Boy."
04/01/2012 - "We present an incidental diagnosis of thoracic GNB, discovered by a chest radiography during a recurrent wheezing unresponsive to bronchodilators. "
|1.||Adrenal Cortex Hormones (Corticosteroids)
|4.||5- (2- (5,6- diethylindan- 2- ylamino)- 1- hydroxyethyl)- 8- hydroxy- 1H- quinolin- 2- one
|1.||Nebulizers and Vaporizers (Inhaler)
|2.||Artificial Respiration (Mechanical Ventilation)
|3.||Metered Dose Inhalers (Metered Dose Inhaler)
|4.||Drug Therapy (Chemotherapy)